Out-of-pocket costs continue to increase for patients who must buy commonly prescribed drugs to treat these five neurological ...

Data from the SENZA-PDN trial showed 10 kHz SCS yielded long-term, clinically meaningful reductions in HbA1c and weight in patients with PDN and T2D.

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) stock is trading higher on Monday after the company released new preclinical ...

In addition, these factors also stimulate inflammation-related damage to the nervous system, contributing to ...

Living with a chronic pain condition can make everyday tasks more challenging. For some people in Southern Utah dealing with ...

Research shows neuropathy can be more severe and more common in Black breast cancer patients, causing doctors to dial back ...

Out-of-pocket costs for drugs for neurologic diseases such as MS, Parkinson's and Alzheimer's disease are climbing sharply, ...

The 12-year-old American boy ate only French fries, hamburgers, ranch dressing, glazed donuts and fruit juice for days, until ...

People with multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, and that amount soared to $2,378 annually in 2021, according to a new study. The study  examined the ...

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of ...

Her other medications include duloxetine. She has Alzheimer’s, diabetes, a history of falls, and hypothyroidism. She’s had three mini strokes and been diagnosed with congestive heart failure. Is there ...